The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

The complications portend a rise in the arrhythmia, and also in mortality, with an average time to event of 7 years.

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

Sreek Vemulapalli and Roseann White explain the statistical challenges that can arise while collecting longer-term follow-up data during clinical trials.

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.

The writing committee says collaborative efforts and patient-level perspective can improve management of pain in this ...

While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

The data are observational but intuitive, say experts. Further work might define where T-TEER’s greatest benefit lies.

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...